Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-grade and High-grade Carcinomas

Keywords

Serous fluid, Serous ovarian cancer, Ovarian carcinomas, Biology, Cancer research

References

• MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells忠重 波部 — 2007
• Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductaseGarth Powis, Peter Wipf, Stephen M. Lynch — 2006
• The Genetic Basis of Human CancerBert Vogelstein, Kenneth W. Kinzler — 1997
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Ie‐Ming Shih, Robert J. Kurman — 2004
• p53 gene mutations and protein accumulation in human ovarian cancer.Jolanta Kupryjańczyk, Ann D. Thor, Roberta L. Beauchamp — 1993
• Notch3 gene amplification in ovarian cancer.Joon T. Park, Mei Li, Kentaro Nakayama — 2006
• AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.J Q Cheng, Andrew K. Godwin, Alfonso Bellacosa — 1992
• High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and AmplificationsKylie L. Gorringe, Sharoni Jacobs, Ella R. Thompson — 2007
• Transcript map of the 8p23 putative tumor suppressor region.Paul C. Sun, Ravindra Uppaluri, Amy P. Schmidt — 2001
• Apply innovative technologies to explore cancer genomeIe‐Ming Shih, Tian‐Li Wang — 2005
• Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.Rong Wu, Lin Lin, David G. Beer — 2003
• Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.Hiroshi Tsuda, Michael J. Birrer, Yoichi M. Ito — 2004
• Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.Peter Schraml, Georg Schwerdtfeger, Felix Burkhalter — 2003
• Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.Tian‐Li Wang, Luis A. Díaz, Katharine Romans — 2004
• DOCK4, a GTPase activator, is disrupted during tumorigenesis.Vijay Yajnik, Charles Paulding, Raffaella Sordella — 2003
• Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma.Ie‐Ming Shih, Jim Jinn‐Chyuan Sheu, Antonio Santillan — 2005
• Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrestFang Sun, Hanjiang Fu, Qin Liu — 2008
• Homozygous deletion of MKK4 in ovarian serous carcinomaKentaro Nakayama, Naomi Nakayama, Ben Davidson — 2006
• Geographical Variations in TP53 Mutational Spectrum in Ovarian CarcinomasAgnieszka Dansonka‐Mieszkowska, Agnieszka H. Ludwig‐Słomczyńska, Ewa Kraszewska — 2006
• Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.Tsung-Cheng Chang, Erik A. Wentzel, Oliver A. Kent — 2007

Cited by

• Modeling high-grade serous ovarian carcinogenesis from the fallopian tube岡本 — 2011
• Isolation and characterization of cancer stem cells in vitro.Craig Gedye, Laurie Ailles — 2013
• Estudio comparativo entre cirugía primaria y cirugía de intervalo en el estadio iiic del cáncer de ovarioSánchez Iglesias, José Luís — 2014
• Pesquisa de microrrearranjos em genes candidatos a surdez sindrômica e não-sindrômicaDaniela Tiaki Uehara — 2010
• Functional Assessment of the Role of BORIS in Ovarian Cancer Using a Novel In Vivo Model SystemAdam R. Karpf, Michael J. Higgins — 2014
• Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum)Deborah F. DeLair, Robert A. Soslow — 2012
• KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous carcinomaYvonne T.M. Tsang, Michael T. Deavers, Charlotte C. Sun — 2013
• Genomic alterations in familial and sporadic epithelial ovarian carcinomas and their clinical relevanceM. Kamieniak — 2014
• Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian StudyRussell Vang, Douglas A. Levine, Robert A. Soslow — 2016
• Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.Isaiah G. Schauer, Anil K. Sood, Samuel C. Mok — 2011
• Allele-specific signal modeling and normalization improves "In silico detection of genomic deletion types and correction of normal cell contamination in copy number data"Yi Fu, Yue Wang, Douglas A. Levine — 2013
• BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumorYi Fu, Guoqiang Yu, Douglas A. Levine — 2013
• Comparative Analysis of Methods for Identifying Recurrent Copy Number Alterations in CancerXiguo Yuan, Junying Zhang, Shengli Zhang — 2012
• Activation of the MEK – S6 pathway in high-grade ovarian cancersAviva P. Ventura, Sabarinath Venniyil Radhakrishnan, Ann Green — 2010
• An Insightful Assessment on Impact of Local Economic Development Programmes in South Africa and Nigeria: Linking Socio-Cooperative Connections and Youths’ ParticipationPrecious Nwachukwu — 2014
• Clinicopathologic and Immunohistochemical Features of Ovarian Clear Cell Carcinomas in Comparison With Type I and Type II TumorsGian Franco Zannoni, Francesca Morassi, Maria Grazia Prisco — 2012
• Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous CarcinogenesisElisabetta Kuhn, Alan K. Meeker, Tian‐Li Wang — 2010
• Ovarian Cancer Is an Imported Disease: Fact or Fiction?Elisabetta Kuhn, Robert J. Kurman, Ie‐Ming Shih — 2012
• Amplification of The ch19p13.2 NACC1 Locus in Ovarian High-grade Serous CarcinomaIe‐Ming Shih, Kentaro Nakayama, Gang Wu — 2011
• Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkersMarieke A. Vollebergh, Jos Jonkers, Sabine C. Linn — 2011

Related papers

• Expression and diagnostic value of HE4 level in early serous ovarianFan Qun — 2013
• The expression and clinical significance of C1orf106 in low-grade serous ovarian cancerFeifei Song, Xiaojing Chen, Cai-yun Zhou — 2023
• Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancerMiłosz Wilczyński, Ewelina Żytko, Justyna Danielska — 2018
• Low-grade serous ovarian carcinoma: an evolution toward targeted therapyIoannis A. Voutsadakis — 2019
• Expression of CLN3 Gene in Ovarian Serous CancerMing Liu — 2008
• Low-grade serous ovarian cancer: a unique diseaseKathleen M. Schmeler, David M. Gershenson — 2008
• EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian TumorsA E Cîrstea, Alex Emilian Stepan, Roxana Eugenia Zăvoi — 2018
• The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.Kwong‐Kwok Wong, David M. Gershenson — 2007
• Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomasAmelia Hallas-Potts, John C. Dawson, C. Simon Herrington — 2019
• Can TP53 variant negative be high-grade serous ovarian carcinoma? A case seriesLawrence Kasherman, Swati Garg, Naïri Tchrakian — 2021